Humulin Nph

Humulin NPH is a recombinant human insulin (Insulin human, rDNA) supplied as an injectable solution for subcutaneous administration. It is a neutral protamine Hagedorn (NPH) formulation, providing intermediate‑duration glucose‑lowering activity. The product is marketed in the European Union and is available by prescription only. It is intended for use in adults and children with diabetes to help maintain target blood glucose levels as part of a comprehensive management plan.

Humulin NPH is indicated for the long‑term management of hyperglycaemia in patients with diabetes mellitus.

- Type 1 diabetes mellitus as part of a basal insulin regimen. - Type 2 diabetes mellitus when basal insulin is required. - Adjunct to oral antidiabetic agents in type 2 diabetes. - Use in combination with rapid‑acting insulin analogues for intensified therapy. - Pediatric patients with diabetes when a basal insulin is appropriate.

Like all insulin preparations, Humulin NPH may be associated with adverse reactions, most of which are related to its glucose‑lowering action or injection site.

Common: - Hypoglycaemia (low blood glucose) - Injection‑site pain or erythema - Lipodystrophy at the injection site - Weight gain

Serious: - Severe hypoglycaemia with neurological symptoms - Allergic reactions such as urticaria or anaphylaxis - Edema or heart failure exacerbation

When prescribing or using Humulin NPH, clinicians should consider several precautionary measures to minimise risks and ensure safe therapy.

- Assess renal and hepatic function before initiating therapy. - Adjust dose in patients prone to hypoglycaemia, such as the elderly or those with irregular meals. - Monitor blood glucose regularly, especially during dose changes or illness. - Use caution in pregnancy and lactation; benefits must outweigh potential risks. - Evaluate for cardiovascular disease, as fluid retention may worsen heart failure. - Educate patients on proper injection technique to avoid lipohypertrophy.

Humulin NPH can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulin analogues without dose adjustment. - Beta‑blockers that may mask hypoglycaemia symptoms. - MAO‑inhibitors that can potentiate insulin’s glucose‑lowering effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk. - Corticosteroids, which may raise blood glucose and require insulin dose changes. - Thiazide diuretics, which can affect potassium levels and insulin sensitivity.